Navigation Links
Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Date:3/16/2009

l function at low concentrations of Dimebon across multiple experiments, and Dimebon showed potent mitochondrial responses in both stressed and normal cells.

MDV3100

  • Completed enrollment in our Phase 1-2 dose-escalation trial in patients with castration-resistant prostate cancer (CRPC).
  • Presented data from our Phase 1-2 clinical trial at ASCO's 2009 Genitourinary Cancers Symposium showing that MDV3100 consistently demonstrated encouraging anti-tumor activity across dose levels, endpoints and in both pre- and post-chemotherapy groups in the 114 patients who had thus far been followed for 12 weeks or longer. Safety data demonstrated that doses at 240 mg and below were well tolerated.
  • Remain on track to seek FDA approval to begin a pivotal Phase 3 registration study in castration-resistant prostate cancer patients in 2009.
  • Will present additional data from the ongoing Phase 1-2 study at upcoming medical conferences in 2009.

Fourth Quarter and Year-End 2008 Financial Results

Revenue for the fourth quarter and full year of 2008 was $12.6 million, consisting of partial recognition of the non-refundable up-front payment of $225.0 million received from Pfizer in October 2008. The up-front payment was recorded as deferred revenue upon receipt and is being recognized on a straight-line basis over the estimated performance period of the Company's obligations under its collaboration agreement with Pfizer, which the Company presently expects to complete in the first quarter of 2012.

For the twelve months ended December 31, 2008, total operating expenses were $76.8 million, compared with total operating expenses of $33.8 million for the same period in 2007. These figures include non-cash stock-based compensation expense of $8.5 million in the year ended December 3
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
2. Medivation Presents New Data on Dimebons Novel Mechanism of Action
3. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
4. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
5. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
6. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
7. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
8. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
9. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
10. Medivation Announces Participation in Upcoming Conferences
11. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015 /CNW/ - Bioenterprise Corporation is ... newest office in Charlottetown , PEI.  ... Prince Edward Island ADAPT Council for the commercialization of ... forward to working with PEI ADAPT.  They have been ... more than a decade," explains Dave Smardon , ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., a ... therapeutic antibodies, today announced the advancement of ... into IND-enabling studies. The Company,s anti-IL-36R therapeutic ... for generalized pustular psoriasis (GPP), an orphan ... need. ANB019 is wholly owned within AnaptysBio,s proprietary ...
(Date:4/16/2015)...  EMD Serono today announced the US biopharmaceutical ... , appointed Alise Reicin , MD, ... Development.  Dr. Reicin brings extensive research and early/late ... Immunology. She is an accomplished pharmaceutical executive with ... President in various capacities across R&D at MSD ...
(Date:4/16/2015)... Fairleigh Dickinson University ( FDU ... become the Executive Director of the Rothman Institute ... kick-off of the Initiative for Patient Centered Innovation ... under the Rothman Institute of Innovation and Entrepreneurship ... collaboration with FDU’s School of Pharmacy’s Center for ...
Breaking Biology Technology:Bioenterprise Corporation Expands into the Maritimes 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... Chilcott,Limited (Nasdaq: WCRX ) announced today that it ... the market opening on Friday,November 9, 2007. The ... audio webcast,on Friday, November 9, 2007 at 8:00 AM ... call, please dial (888) 503-8171 in the,United States and ...
... The Cervical Spine Now Available In ... ... Trinity,Clinic Neurosurgeon and Director of the Trinity Mother Frances Neuroscience,Institute is the ... that can provide some patients a chance to maintain,motion in their necks ...
... System delivers unmatched out-of-the-box functionality, BENSALEM, ... (Stelex), the market leader in providing enterprise-wide,compliance ... the,Quality Management System (QMS) module for Livelink ... provider of Enterprise Content,Management (ECM) software and ...
Cached Biology Technology:Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck 2Stelex Announce QMS Module for Open Text's Livelink ECM 2Stelex Announce QMS Module for Open Text's Livelink ECM 3
(Date:3/23/2015)...   HOYOS Labs , a leading global authentication ... the Company will demonstrate multiple biometrics-based technologies under its ... Connect:ID on March 23 through 25, 2015, in ... the IEEE Biometric Open Protocol Standard; free biometrics-based consumer ... control system. BOPS was invented by HOYOS Labs and ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Geometry - Global Strategic Business Report" report to their ... Hand Geometry in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... devastated the Gulf of Mexico ecologically and economically. However, a ... the true impact of the disaster on wildlife may be ... the number of recovered animal carcasses will not give a ... believed. "The Deepwater oil spill was the largest in ...
... at Michigan State University has revealed a potential new way ... Howe, biochemistry and molecular biology professor, cites that this defense ... race between plants and herbivores. Howe, in the current ... Sciences, offers insights to understanding the chemical weaponry of ...
... being able to capture the "evanescent" light waves that ... far enough to be "seen" by a conventional lens. ... depending upon the form of light they capture, ... been made from elaborate artificial constructs known as metamaterials. ...
Cached Biology News:Whale and dolphin death toll during Deepwater disaster may have been greatly underestimated 2Whale and dolphin death toll during Deepwater disaster may have been greatly underestimated 3The way to (kill) a bug's heart is through its stomach 2Berkeley Lab researchers make first perovskite-based superlens for the infrared 2Berkeley Lab researchers make first perovskite-based superlens for the infrared 3Berkeley Lab researchers make first perovskite-based superlens for the infrared 4Berkeley Lab researchers make first perovskite-based superlens for the infrared 5
...
... White solid. PROTECT FROM LIGHT. PACKAGED ... compound that acts as a selective, ... PTP1B (IC 50 = 4 ... 403 and PTP1B 298 , ...
...
BD Falcon microtest assay plate. 1536 well 12l, black BD Optilux PS. Polystyrene, nonsterile, no lid (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
Biology Products: